4894 Cuorips
- 9940
- +810+8.87%
Cuorips News
Cuorips: FY2025 Q1 financial report (Japanese standards, consolidated)
Cuorips: Regarding the start of manufacturing samples commissioned by Replictech.
Cuorips: Announcements of individual stocks: Application for subsidy to the California Institute for Regenerative Medicine (CIRM).
Cuorips: (Correction) Partial correction of "Differences between Heart Seat and our product (Human iPS-derived cardiomyocyte sheet)"
Cuorips: Regarding the difference between the HeartSheet discussed at the Pharmaceuticals and Medical Devices Agency's Regenerative and Biological Products Technology Subcommittee on July 19th, and our product (Human iPS cardiomyocyte-derived sheet).
Cuorips: Interim report
Cuorips: Internal Control Report - 8th Term (April 1, 2023 - March 31, 2024)
Cuorips: Confirmatory letter.
Cuorips: Securities Report - 8th term (April 1, 2023 to March 31, 2024)
Cuorips: Matters related to business plans and growth potential.
Cuorips: Announcements of individual stocks regarding the establishment of a subsidiary in USA.
Cuorips: Corporate Governance Report June 26, 2024
Cuorips: Announcements of individual stocks: Change of application period using long-term data in clinical trials of iPS-derived myocardial cell sheets.
Cuorips: Part of the Correction Notice for the 8th Regular General Meeting of Shareholders Invitation
Cuorips: Independent Company Executives Declaration
Cuorips: Change report.
Cuorips: Notice of Convening the Regular Shareholders' Meeting in 2024 and Other Electronic Provision Measures (Omitted Matters in Written Form)
Cuorips: Notice of Convening Regular Shareholders' Meeting for the Year 2024.
Cuorips: Notice of provision of cardiomyocyte sheets for treatment of dilated heart disease using human iPS cell-derived cardiomyocyte sheets
Cuorips: About some reports about our company
Analysis
Price Target
No Data
No Data